Breaks Categories: Stock Spotlights

TuesdayDec 20, 2016 1:37 pm

NetworkNewsBreaks – OurPet’s Company (OPCO) Sets Sights on Open Market for Interactive Dog Toys

OurPet’s Company (OTCQX: OPCO) recently opened up about the details of its continued growth in the booming non-food pet product industry. With the majority of the company’s success linked to the cat market, OPCO plans to exploit the open market for interactive dog toys. “Approximately 61% of OPCO’s revenue comes from the cat market, mostly toys and accessories together with waste and odor products, while 38% comes from the dog market, mostly feeding and storage products. However, OPCO also sees untouched opportunities in the dog toys area. As with its cat toys, OPCO has put research into the sensations and…

Continue Reading

MondayDec 19, 2016 12:20 pm

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Combines Solid Security with Latest Technology for E-Commerce Payment Solutions

Net Element (NASDAQ: NETE) continues to be a step ahead of the game with its innovative payment platform, PayOnline. “Internet payment processing businesses rarely achieve success without the latest technology, the highest levels of security or a personalized approach to every customer. Reliability and stability are also features that customers look at when choosing an e-commerce payments acceptance vendor. It is little surprise, then, that Net Element and PayOnline embody these characteristics while also thriving in the innovation and product development areas. Attributes such as these characterize the companies differently from their competitors, and so do the ground-breaking products they continue…

Continue Reading

FridayDec 16, 2016 2:14 pm

NetworkNewsBreaks – National Waste Management Holdings (NWMH) Tackles Ever-Growing Electronic Waste

With technology advancing by the minute, everyone is after a newer, more up-to-date model of their phone, computer, laptop, or other device. Where their old device ends up isn’t something most people worry about. Luckily, there are companies who handle e-waste. “Since the dawn of the electronic and digital ages, varieties of electronic waste (e-waste), which include computers and associated devices and materials, have multiplied. This mountain of waste poses a troubling challenge to the health of the planet and its inhabitants. Thankfully, it is a challenge that has been taken on by Florida-based National Waste Management Holdings (OTC: NWMH).…

Continue Reading

FridayDec 16, 2016 2:13 pm

NetworkNewsBreaks – LightPath Technologies, Inc. (NASDAQ: LPTH) Prices Public Offering of 7M Shares of Class A Common Stock

Shares of LightPath Technologies (NASDAQ: LPTH) are higher this morning after the company priced its underwritten public offering of seven million shares of its Class A common stock at a price of $1.21 per share. It also granted to the underwriters a 45-day option to acquire an additional one million shares to cover over-allotments in connection with the offering, of which the opportunity to acquire 300,000 shares has been exercised. The company expects to use the anticipated $8.15 million proceeds of the offering toward its acquisition of ISP Optics Corporation. The offering is expected to close December 21, 2016. To…

Continue Reading

FridayDec 16, 2016 2:09 pm

NetworkNewsBreaks – GainClients (GCLT) Exclusive HomeSearch Platform Delivers Custom Results to Consumers

Potential home owners generally know what they want in a new home and don’t want to waste time looking at houses that don’t meet their needs. With the new HomeSearch platform from GainClients, homebuyers can save time and energy by essentially eliminating homes that don’t fit their search criteria.  “With this growing demand and a consistently smaller inventory, finding the right home will become more difficult than ever. GainClients, Inc. (OTC: GCLT), a leading provider of technology solutions for the real estate industry, aims at helping consumers look for and identify the right home for them via a comprehensive yet…

Continue Reading

ThursdayDec 15, 2016 1:25 pm

NetworkNewsBreaks – Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) Resolves Patent Litigation Regarding Schizophrenia Treatment

Vanda Pharmaceuticals (NASDAQ: VNDA) recently resolved its patent litigation against Apotex regarding Apotex's Abbreviated New Drug Application seeking approval of its generic version of Vanda's Fanapt® (iloperidone). Under a licensing agreement, Vanda has granted Apotex a non-exclusive license to manufacture and commercialize its version of Fanapt® in the U.S., effective November 2, 2027. Fanapt® in 2009 was approved by the FDA for the treatment of schizophrenia in adults. In 2012, the drug was approved for marketing in Israel and Argentina. To view the full press release, visit: http://nnw.fm/XSt0U About Vanda Pharmaceuticals Inc. Vanda is a specialty pharmaceutical company focused on…

Continue Reading

ThursdayDec 15, 2016 1:21 pm

NetworkNewsBreaks – Ocera Therapeutics, Inc. (NASDAQ: OCRX) Targets Hepatic Encephalopathy, a Complication of Liver Cirrhosis, with OCR-002

Ocera Therapeutics (NASDAQ: OCRX) is focused on the development of OCR-002 (ornithine phenylacetate) to treat hyperammonemia and subsequent hepatic encephalopathy (HE). An estimated eight million people in the U.S. suffer from chronic liver disease and approximately one million suffer from liver cirrhosis. HE is a debilitating and progressive complication of liver cirrhosis or liver failure marked by mental changes including confusion, impaired motor skills, and disorientation. Severe HE can cause stupor, coma and even death. Currently, there are no drug treatments that can be given intravenously to hospitalized patients with acute HE. To learn more visit www.ocerainc.com About Ocera Ocera…

Continue Reading

ThursdayDec 15, 2016 1:18 pm

NetworkNewsBreaks – CytoDyn Inc. (CYDY) Advances Clinical Trials for PRO 140 for HIV Infection

Cytodyn (OTCQB: CYDY) is focused on enhancing the lives of people with infectious diseases through the development of new antibody treatments to battle human immunodeficiency virus (HIV) infection. An estimated 1.2 million people in the United States were living with HIV at the end of 2013, the most recent year for which this information is available. Cytodyn recently reported the first several patients have been treated in its phase 3 clinical trial with PRO 140, its proprietary drug that can significantly reduce viral burden in people infected with HIV. PRO 140 works by blocking the HIV co-receptor CCR5 on T-cells…

Continue Reading

WednesdayDec 14, 2016 1:58 pm

NetworkNewsBreaks – Vericel (NASDAQ: VCEL) Receives FDA Approval for MACI®; Shares Soar

Shares of Vericel Corp. (NASDAQ: VCEL) are up more than 60% mid-day after the company broke news of the approval of MACI® (autologous cultured chondrocytes on porcine collagen membrane) by the U.S. Food and Drug Administration (FDA) for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. MACI is the first FDA-approved cellularized scaffold product that applies tissue engineering processes to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. "We believe that the introduction of MACI, along with investments to expand our commercial organization…

Continue Reading

TuesdayDec 13, 2016 2:44 pm

NetworkNewsBreaks – Achaogen, Inc. (AKAO) Proposes Common Stock Public Offering, Proceeds to Advance Plazomicin

Achaogen (NASDAQ: AKAO) has initiated an underwritten public offering of up to 5,750,000 shares of its common stock, all of which are offered by the company. Additionally, Achaogen expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 862,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The company said it intends to use the net proceeds to fund the ongoing development and preparation for potential commercialization of its lead candidate plazomicin, for which the company yesterday announced positive results in phase 3 cUTI and CRE clinical…

Continue Reading